Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
- 6 May 2009
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (2) , 77-88
Abstract
Trastuzumab, a monoclonal antibody that blocks HER-2 receptor, improves the survival of women with HER-2-positive early and advanced breast cancer when given with chemotherapy. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine. Importantly, cardiac toxicity, manifested as symptomatic congestive heart failure or asymptomatic left ventricular ejection fraction decline, has been reported in some of the patients receiving these novel anti-HER-2 therapies, particularly when these drugs are used following anthracyclines, whose cardiotoxic potential has been recognized for decades. This review will focus on the incidence, natural history, underlying mechanisms, management, and areas of uncertainty regarding trastuzumab-and lapatinib-induced cardiotoxicity.Keywords
This publication has 47 references indexed in Scilit:
- In ReplyJournal of Clinical Oncology, 2008
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant TrialJournal of Clinical Oncology, 2007
- Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and DiseaseCirculation, 2007
- Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cellsProceedings of the National Academy of Sciences, 2007
- Changes in shoulder muscle size and activity following treatment for breast cancerBreast Cancer Research and Treatment, 2007
- Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same RegimenClinical Cancer Research, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Continuation of Trastuzumab Beyond Disease ProgressionJournal of Clinical Oncology, 2005
- Letter Regarding Article by Okoshi et al, “Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of β-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion”Circulation, 2005
- Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac MuscleCirculation, 2004